{"schema_version":"1.0","type":"article","title":"大藥廠不是沒錢，是交易條件變窄了：M&A beta 降溫後，asset alpha 為何可能上升","url":"https://drugnews.com.tw/articles/2026-09-18-ma-beta-asset-alpha-biopharma-deals.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-18-ma-beta-asset-alpha-biopharma-deals.md","lang":"zh-Hant","date":"2026-09-18","publish_at":"2026-09-18T08:00:00+08:00","updated_at":"2026-09-18","category":"商業分析系列","topic":"商業分析系列","tags":["M&A","biotech","asset alpha","IQVIA","EY","授權交易"],"summary":"大型併購共同溢價降溫不代表買方沒錢；當臨床證據、上市時點、權利結構與團隊承接能力都能驗證，少數資產的個別價值反而可能上升。","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"圖 1｜M&A beta 降，asset alpha 為何可能升","url":"https://drugnews.com.tw/assets/articles/ma-beta-asset-alpha-biopharma-deals/01_MA_beta%E4%B8%8B%E9%99%8D%E8%88%87asset_alpha%E4%B8%8A%E5%8D%87_typed_v1.png"},{"alt":"圖 2｜買方創新資產補庫狀態分岔","url":"https://drugnews.com.tw/assets/articles/ma-beta-asset-alpha-biopharma-deals/02_%E8%B2%B7%E6%96%B9%E5%89%B5%E6%96%B0%E8%B3%87%E7%94%A2%E8%A3%9C%E5%BA%AB%E7%8B%80%E6%85%8B%E5%88%86%E5%B2%94_typed_v1.png"},{"alt":"圖 3｜資產可驗證性四道閘門","url":"https://drugnews.com.tw/assets/articles/ma-beta-asset-alpha-biopharma-deals/03_%E8%B3%87%E7%94%A2%E5%8F%AF%E9%A9%97%E8%AD%89%E6%80%A7%E5%9B%9B%E9%81%93%E9%96%98%E9%96%80_typed_v1.png"},{"alt":"圖 4｜中國 biotech 的權利與交易邊界","url":"https://drugnews.com.tw/assets/articles/ma-beta-asset-alpha-biopharma-deals/04_%E4%B8%AD%E5%9C%8Bbiotech%E6%AC%8A%E5%88%A9%E8%88%87%E4%BA%A4%E6%98%93%E9%82%8A%E7%95%8C_typed_v1.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/ma-beta-asset-alpha-biopharma-deals/01_MA_beta%E4%B8%8B%E9%99%8D%E8%88%87asset_alpha%E4%B8%8A%E5%8D%87_typed_v1.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-18）。大藥廠不是沒錢，是交易條件變窄了：M&A beta 降溫後，asset alpha 為何可能上升。https://drugnews.com.tw/articles/2026-09-18-ma-beta-asset-alpha-biopharma-deals.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}